文献速递心境障碍

山竹果皮提取物辅助治疗双相抑郁:24周随机对照试验

The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial.
PubMed 文献 · Br J Psychiatry · 2025-07-10

这项为期28周的随机、多中心、双盲、安慰剂对照试验,纳入双相I或II型且至少中度抑郁症状的成人,比较山竹果皮提取物辅助治疗与安慰剂。结果显示,24周时山竹组在心境症状、双相严重度临床印象和社会功能方面较基线改善显著优于对照组,但整体抑郁症状变化两组无实质差异,且差异在停药后第28周减弱。结论认为辅助山竹治疗对双相抑郁的心境和功能症状疗效有限。

要点

  • 24周时山竹组心境症状、临床总体印象和社会功能较基线改善显著优于安慰剂。
  • 整体抑郁症状变化两组间无实质差异,主要假设仅获有限支持。
  • 停药后第28周评估时组间差异减弱,疗效未持续。

核心结论

  • 辅助山竹果皮提取物对双相抑郁的心境和功能症状疗效有限,对躁狂症状和生活质量无效,需重复验证。

研究设计与样本

  • 28周随机、多中心、双盲、安慰剂对照试验,前瞻性注册于澳大利亚新西兰临床试验注册处(ACTRN12616000028404)。
  • 纳入18岁及以上、诊断为双相I或II型且至少中度抑郁症状的参与者。
  • 共1016人 initially approached or volunteered,712人未进入筛查,另有152人筛查排除。

主要发现

  • 经过24周治疗,抑郁症状总体变化两组间无实质差异。
  • 24周时山竹组较基线在心境症状、双相严重度临床印象和社会功能方面改善显著大于对照组。
  • 上述差异在停药后第28周评估时减弱。
  • 山竹组对躁狂症状和生活质量未见显著效果。

临床怎么用

  • 现有证据不足以推荐山竹果皮提取物作为双相抑郁的常规辅助治疗。
  • 临床决策应继续以循证心境稳定剂和心理社会干预为基础。

局限性

  • 疗效在停药后减弱,提示短期获益可能不持久。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bipolar depression remains difficult to treat, and people often experience ongoing residual symptoms, decreased functioning and impaired quality of life. Adjunctive therapies targeting novel pathways can provide wider treatment options and improve clinical outcomes. Garcinia mangostana Linn. (mangosteen) pericarp has serotonogenic, antioxidant anti-inflammatory and neurogenic properties of relevance to the mechanisms of bipolar depression. AIMS: The current 28-week randomised, multisite, double-blind, placebo-controlled trial investigated mangosteen pericarp extract as an adjunct to treatment-as-usual for treatment of bipolar depression. METHOD: This trial was prospectively registered on the Australia New Zealand Clinical Trials Registry (no. ACTRN12616000028404). Participants aged 18 years and older with a diagnosis of bipolar I or II and with at least moderate depressive symptoms were eligible for the study. A total of 1016 participants were initially approached or volunteered for the study, of whom 712 did not progress to screening, with an additional 152 screened out. Seventy participants were randomly allocated to mangosteen and 82 to a placebo control. Fifty participants in the mangosteen and 64 participants in the placebo condition completed the treatment period and were analysed. RESULTS: Results indicated limited support for the primary hypothesis of superior depression symptom reduction following 24 weeks of treatment. Although overall changes in depressive symptoms did not substantially differ between conditions over the course of the trial, we observed significantly greater improvements for the mangosteen condition at 24 weeks, compared with baseline, for mood symptoms, clinical impressions of bipolar severity and social functioning compared with controls. These differences were attenuated at week 28 post-discontinuation assessment. CONCLUSIONS: Adjunctive mangosteen pericarp treatment appeared to have limited efficacy in mood and functional symptoms associated with bipolar disorder, but not with manic symptoms or quality of life, suggesting a novel therapeutic approach that should be verified by replication.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dean OM, Cotton SM, Ashton MM, et al. The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial. Br J Psychiatry. 2025. PMID: 40637133. doi:10.1192/bjp.2025.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。